ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

WOBURN, Massachusetts, October 12, 2010 – ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE
4568) today announced the expansion of their research, development and
license agreement for the discovery of novel kinase inhibitors in the field
of oncology. This expanded agreement establishes a third therapeutic target,
with an option for a fourth, in the field of [...]

BiondVax Begins Phase IIa Study for Universal Flu Vaccine

NESS ZIONA, Israel, October 11, 2010 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX) (www.biondvax.com/), an
Israeli biopharmaceutical company at the forefront of global efforts towards
the development of a Universal Influenza Vaccine, today announced that it has
begun to immunize subjects in a Phase IIa clinical trial of the
Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the
safety [...]

Global Experts Debate Solutions for Preventing Healthcare Acquired Infections at the 2010 International Conference of The Hospital Infection Society

ASP Sponsors Educational Symposium to Strengthen Infection Prevention Efforts and Promote Better Patient Care

LONDON, October 11, 2010 – At this week's international conference of the Hospital Infection Society
in Liverpool, United Kingdom, the world's leading experts in healthcare
acquired infections will gather to share their latest research and discuss
new ways of combatting diseases like MRSA and [...]

Shire Appoints Philip J. Vickers, PhD as Senior Vice President of Research & Development for Human Genetic Therapies Business

NYON, Switzerland and CAMBRIDGE, Massachusetts, October 11, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that Philip J. Vickers, PhD, has
been appointed Senior Vice President of Research & Development (R&D) for its
Human Genetic Therapies (HGT) business. In this position, Dr. Vickers will be
responsible for leading global R&D for [...]

Abiraterone Acetate Significantly Improved Overall Survival for Patients With Metastatic Advanced Prostate Cancer

Note: Data in This Release Correspond to ESMO Abstract LBA5
BEERSE, Belgium, October 11, 2010 – Results from a pre-specified interim analysis of a randomised,
placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients
treated with the investigational agent abiraterone acetate plus low dose
prednisone/prednisolone showed a significant improvement in overall survival
compared to patients treated with prednisone/prednisolone plus placebo. [...]

Health Robotics Expands Operations Into Bosnia, Croatia, Finland, Macedonia, Montenegro, Serbia, and Slovenia

BOZEN, Sud-Tirol, Italy, October 11, 2010 – Health Robotics today announced that it recently signed exclusive
distribution agreements for its CytoCare, i.v.STATION, and i.v.SOFT
world-leading technologies in seven new European countries with regional
industry leaders Newico and Apta Medica, rapidly continuing on its worldwide
quest to pervasively provide safe and cost-effective Intravenous (IV)
Admixture Compounding Automation to hospitals all [...]

The Harley Medical Group Announces Rise in Breast Surgery Procedures in Ireland

DUN LOAGHAIRE, Ireland, October 11, 2010 – The Harley Medical Group, Ireland's leading cosmetic surgery provider,
has revealed breast surgery is top of the ops for the 23rd year running and
the fastest growing sector of cosmetic surgery. The Harley Medical Group has
seen a positive increase on last year's enquiries. While breast reductions
are becoming more popular [...]

Final Analysis of Landmark IPASS Study Confirms That IRESSA (Gefitinib) is a Valuable Option for the First-Line Treatment of Patients With Advanced NSCLC With EGFR Activating Mutations

MILAN, October 11, 2010 – This press release has been made available on worldwide (excluding US)
press communication media for the benefit of correspondents writing for the
medical professional press. Differing national legislation, codes of
practice, medical practice etc mean that you should contact your local AZ
press office to obtain information designed for use in your country.
Not [...]

Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874)

Data Compares Briakinumab (ABT-874) to Etanercept, Methotrexate and Placebo in Psoriasis

ABBOTT PARK, Illinois, October 11, 2010 – In four separate pivotal clinical studies presented on Friday, a greater
percentage of moderate to severe chronic plaque psoriasis patients treated
with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874),
achieved 75 percent or better skin clearance rates than those treated with
etanercept [...]

HeartSine Technologies Honored With Belfast Ambassador Award at Belfast Business Top 50 Event

Award goes to the company for pioneering business in developing areas of Belfast.

STORMONT, BELFAST, Northern Ireland, October 11, 2010 – HeartSine Technologies, Inc. (www.heartsine.com) was honored with
the Belfast Ambassador Award at the sixth annual Belfast Business Top 50
event in Stormont, Belfast. The award was presented to the company by the
Belfast Media Group (belfastmedia.com) for [...]